HD-OPM Archive
Topics › Supplements & vitamins

Nicotinamide riboside failed in phase 3 early Parkinson's trial, symptoms modestly worse

Louis Nervegna · Nov 06, 2026 · ♥ 3 reactions · 1 comments · original Facebook post
Supplements & vitaminsBrain health & dementiaAging & longevity
AI summary & key facts

Louis shares a JAMA-reported phase 3 trial of oral nicotinamide riboside (NR), a popular NAD+ booster, in early Parkinson's disease. It did not improve outcomes versus placebo at 52 weeks and patients on NR had modestly worse MDS-UPDRS scores. Louis says it shows the supplement may have downsides in some conditions.

Nicotinamide riboside (NR) failed as a treatment for early Parkinson’s disease.

It actually made symptoms modestly worse, by the end of one year.

This is a supplement commonly taken for “anti-aging” to raise levels of NAD+. This study highlights that it may have downsides in certain conditions.

Quoted from the original post:

In a phase 3 trial of oral Nicotinamide Riboside for early Parkinson’s Disease treatment, the intervention did not improve clinical outcomes compared with placebo at 52 weeks. Patients receiving nicotinamide riboside had modestly worse scores on the MDS-UPDRS (Movement Disorder Society Unified Parkinson Disease Rating Scale), a measure of motor and non-motor symptoms. The findings are clinically relevant given widespread use of this supplement and ongoing related trials.

📌 Learn more:

Paper · JAMA · 2026Nicotinamide Riboside for Patients With Early-Stage Parkinson DiseaseImportance Nicotinamide riboside, a nicotinamide adenine dinucleotide precursor, has been proposed as a potential disease-modifying therapy for Parkinson disease based on preclinical and early studies. Whether prolonged oral nicotinamide riboside improves clinical outcomes in Parkinson disease is unknown. Objective To determine whether nicotinamide riboside improves clinical outcomes in Parkinson disease compared…jamanetwork.com

#nrHD #nadHD #parkinsonsHD #vitaminb3HD

Research cited

← newer: GLP-1 drugs vs metformin in obese prediabetes: 31% less diabolder: Yale: taurine loss triggers NLRP3 inflammasome; raising taur →